Mar 28, 2012 by Brian Orelli, PhDDrug Approved, Sales Battle BeginsAffymax gets Omontys approved, and the battle with Amgen begins.
Mar 27, 2012 by Brian Orelli, PhDFDA Talks Heart Trials for Obesity DrugsA two-day advisory committee discusses heart trials for obesity drugs.
Mar 27, 2012 by Brian Orelli, PhDWill the FDA Approve Chelsea's Northera?Orphan disease or not, chances don't look good.
Mar 27, 2012 by Brian Orelli, PhDCall It an "Almost Approval"MAP gets a CRL, but Levadex lives to fight another day.
Mar 26, 2012 by Brian Orelli, PhDWill the FDA Approve Affymax's Peginesatide?More likely than not, but don't forget the "not."
Mar 23, 2012 by Brian Orelli, PhDWill the FDA Approve MAP's Levadex?Or will it give investors a headache?
Mar 21, 2012 by Brian Orelli, PhDPatent Secured. Next Stop: Sale?An Amarin sale looks more likely, but it's not quite time yet.
Mar 21, 2012 by Brian Orelli, PhDAdvisory Panel Pans Drug, Investors Shrug?It's all about ponatinib for ARIAD.
Mar 21, 2012 by Brian Orelli, PhDKeep Your Expectations in CheckBioSante hopes the Pill-Plus will raise sexual desire and keep women from getting pregnant.
Mar 20, 2012 by Brian Orelli, PhDDepressing Clinical Trial NewsThis adjunct depression treatment is done.
Mar 19, 2012 by Brian Orelli, PhDAn FDA Advisory Panel DoubleheaderGlaxo's Votrient, and Taltorvic from Merck and Ariad, head in front of the firing squad.
Mar 17, 2012 by Brian Orelli, PhDBiotechs Have No Business in This IndicationLeave the heart drugs to pharma.
Mar 16, 2012 by Brian Orelli, PhDDrug Pricing Takes This Biotech on a RollercoasterGermany toys with InterMune.
Mar 15, 2012 by Brian Orelli, PhDBeing Right in Biotech Is Only Half the BattleBetting with the grain isn't all that profitable.
Mar 15, 2012 by Brian Orelli, PhD3 Biotechs You Should Have Sold Years AgoEven with good news, these biotechs are long-term losers.
Mar 14, 2012 by Brian Orelli, PhDPfizer's $200 Million MistakeThe pharma giant rethinks its generic insulin strategy.
Mar 13, 2012 by Brian Orelli, PhDA Drug Class Back From the Dead?An FDA advisory panel backs anti-nerve growth factor drugs despite side effects.
Mar 12, 2012 by Brian Orelli, PhDTranzyme Investors: Why Shares Just Got HalvedTranzyme's ulimorelin fails as placebo performs better than expected.
